Donepezil improved memory in multiple sclerosis in a randomized clinical trial.
Tsao
Jack W
JW
Heilman
Kenneth M
KM
D016477:Artifacts; D018680:Cholinergic Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D000077265:Donepezil; D004347:Drug Interactions / Q000502:physiology; D006801:Humans; D007189:Indans / Q000494:pharmacology* / Q000627:therapeutic use; D008569:Memory Disorders / Q000188:drug therapy* / Q000209:etiology* / Q000378:metabolism; D018697:Nootropic Agents / Q000494:pharmacology / Q000627:therapeutic use; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D015203:Reproducibility of Results; D012107:Research Design / Q000592:standards; D016896:Treatment Outcome; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy*
D018680:Cholinergic Antagonists; D002800:Cholinesterase Inhibitors; D007189:Indans; D018697:Nootropic Agents; D010880:Piperidines; D000077265:Donepezil